Emami's unsuccessful attempt to acquire Paras Pharma may boost its short-term outlook, but the development will put pressure to identify other suitable targets to stay competitive in the segment.
The stock of Zydus Wellness has more than doubled in the past nine months and is currently trading at a price-earning multiple of 43.
A successful approval for Aricept should improve investor confidence in Ranbaxy’s ability to convert its FTF applications.
Despite Karuturi’s stagnant earning per share (EPS) in the past few quarters, its stock price movement has been quite volatile.
A ramp-up in its deal with Pfizer resulted in a decent growth in its US and Europe sales. The net profit also got a boost from a forex gain of Rs 76.2 crore.
As per the deal, Biocon will conduct clinical development and regulatory filings while Pfizer will get the exclusive rights to market these products in most markets.
The merger will help GCPL to reduce its dependence on soap products and also tackle high raw material cost caused by inflation in the soap segment.
Delhi-based Koutons Retail India has lost over 40% of its market capitalisation in the past five trading sessions. Its stock closed at an all-time low on Thursday.
After lagging behind the Sensex for the past one month, the BSE FMCG Index outperformed the broader index last week.
The scrip of Bata India, biggest footwear retailer in the country, hit an all-time high. Compared to a 16% gains in the benchmark Sensex, the company’s stock has more than doubled in the past one year.
- No blogs yet have been written by the author, we’re sure the author will contribute one soon